JP2013506682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506682A5 JP2013506682A5 JP2012532299A JP2012532299A JP2013506682A5 JP 2013506682 A5 JP2013506682 A5 JP 2013506682A5 JP 2012532299 A JP2012532299 A JP 2012532299A JP 2012532299 A JP2012532299 A JP 2012532299A JP 2013506682 A5 JP2013506682 A5 JP 2013506682A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutical composition
- seq
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 70
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 102000011931 Nucleoproteins Human genes 0.000 claims description 6
- 108010061100 Nucleoproteins Proteins 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000007922 nasal spray Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 108060003393 Granulin Proteins 0.000 claims description 3
- 102000054766 genetic haplotypes Human genes 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene group Chemical group CC(C)=CCC\C(\C)=C\CC\C(\C)=C\CC\C=C(/C)\CC\C=C(/C)\CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 229940124590 live attenuated vaccine Drugs 0.000 claims 1
- 229940023012 live-attenuated vaccine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 239000000872 buffer Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24703809P | 2009-09-30 | 2009-09-30 | |
| US61/247,038 | 2009-09-30 | ||
| PCT/US2010/050836 WO2011041490A1 (en) | 2009-09-30 | 2010-09-30 | Peptides for inducing heterosubtypic influenza t cell responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013506682A JP2013506682A (ja) | 2013-02-28 |
| JP2013506682A5 true JP2013506682A5 (enExample) | 2013-11-14 |
Family
ID=43780640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532299A Pending JP2013506682A (ja) | 2009-09-30 | 2010-09-30 | 異種亜型インフルエンザｔ細胞応答を誘発するためのペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9265822B2 (enExample) |
| EP (1) | EP2482834A4 (enExample) |
| JP (1) | JP2013506682A (enExample) |
| AU (1) | AU2010300623A1 (enExample) |
| CA (1) | CA2775720A1 (enExample) |
| WO (1) | WO2011041490A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103648491B (zh) * | 2011-04-08 | 2017-07-14 | 法国国家健康医学研究院 | 用于抑制流感病毒复制的方法和药物组合物 |
| CN104436157A (zh) * | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
| US10821164B2 (en) | 2015-06-23 | 2020-11-03 | Saint Louis University | Peptides for inducing Chagas disease responses |
| CN111148528A (zh) | 2016-12-28 | 2020-05-12 | 英福瓦克思公司 | 流感疫苗 |
| US12247053B2 (en) | 2018-10-26 | 2025-03-11 | Saint Louis University | Peptides for inducing heterosubtypic influenza T cell responses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585461A (en) * | 1994-03-24 | 1996-12-17 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
| US7094767B2 (en) * | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
| WO1996010631A1 (en) * | 1994-09-30 | 1996-04-11 | St. Jude Children's Research Hospital | Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| EP1064022A4 (en) * | 1998-03-13 | 2004-09-29 | Epimmune Inc | HLA BINDING PEPTIDES AND THEIR APPLICATIONS |
| US7756644B2 (en) | 2005-05-12 | 2010-07-13 | Merck & Co., Inc. | System and method for automated selection of T-cell epitopes |
| EP2012829A4 (en) * | 2006-04-24 | 2010-04-21 | Protelix Inc | PROCESS FOR PRODUCING VIRAL VACCINE AND THERAPEUTIC PEPTIDE ANTIGENS |
| AU2007314550A1 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| WO2008039267A2 (en) * | 2006-07-21 | 2008-04-03 | Pharmexa Inc. | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
| AU2007306102B2 (en) | 2006-10-11 | 2012-02-23 | Antitope Limited | T cell epitope databases |
-
2010
- 2010-09-30 AU AU2010300623A patent/AU2010300623A1/en not_active Abandoned
- 2010-09-30 US US12/895,289 patent/US9265822B2/en active Active
- 2010-09-30 WO PCT/US2010/050836 patent/WO2011041490A1/en not_active Ceased
- 2010-09-30 EP EP10821219.2A patent/EP2482834A4/en not_active Withdrawn
- 2010-09-30 JP JP2012532299A patent/JP2013506682A/ja active Pending
- 2010-09-30 CA CA2775720A patent/CA2775720A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500001A5 (enExample) | ||
| CN104043120B (zh) | 乙型肝炎疫苗 | |
| JP2011512123A5 (enExample) | ||
| JP2013506682A5 (enExample) | ||
| CN106659777A (zh) | 免疫原性组合产品 | |
| EP2331125A1 (en) | Immunotherapy for chronic hepatitis c virus infection | |
| MX382968B (es) | Vacuna de emergencia basada en péptidos sintéticos contra la fiebre aftosa. | |
| Wells et al. | Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity | |
| EP4138856A1 (en) | A nano-enabled vaccination approach for coronavirus disease (covid-19) and other viral diseases | |
| Cadar et al. | Targeting the hallmarks of aging to improve influenza vaccine responses in older adults | |
| JP2014502961A5 (enExample) | ||
| US20230143215A1 (en) | Immunization against sars-cov-related diseases | |
| JP2015524802A5 (enExample) | ||
| RU2012127358A (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| Bracci et al. | Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus | |
| Liu et al. | Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice | |
| Boonnak et al. | Antigen-activated dendritic cells ameliorate influenza A infections | |
| JP2020515283A5 (enExample) | ||
| JP2014515595A5 (enExample) | ||
| Jo et al. | Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer | |
| KR20200125632A (ko) | 분말 제제, 카트리지 및 디바이스 | |
| Partidos et al. | Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides | |
| JP2012527867A5 (enExample) | ||
| JP2016535015A5 (enExample) | ||
| EP2501396B1 (en) | Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease |